Kairos Pharma Acquires Exclusive Rights to CL-273 From OrbiMed and Torrey Pines Backed Celyn Therapeutics for EGFR-Mutant Lung Cancer Treatment

Kairos Pharma has signed binding terms to acquire CL-273 from Celyn Therapeutics, backed by OrbiMed and Torrey Pines Investment. CL-273 is a wild-type-sparing pan-EGFR small-molecule inhibitor designed to target resistant mutations that develop when using EGFR tyrosine kinase inhibitors. The transaction is expected to be value-accretive and align Kairos Pharma with OrbiMed's track record in building category-defining oncology companies.